Real-world Retention and Clinical Effectiveness of Secukinumab for Psoriatic Arthritis: Results from the CanSpA Research Network

Psoriatic arthritis (PsA) is an immune-mediated disease characterized by pain, stiffness, and swelling of peripheral joints, with an estimated prevalence in Canada of 0.45%. Treatment aims to minimize disease activity, reduce progression of damage, and improve quality of life. Secukinumab is a biologic disease-modifying antirheumatic drug (bDMARD) that has demonstrated efficacy and safety for PsA in clinical trials, however there is limited real-world evidence on its use in Canada. The objective of this study was to use the Canadian Spondyloarthritis (CanSpA) Research Network to describe realworld retention and effectiveness of secukinumab among Canadian patients with PsA.Observational cohort study of Canadian PsA patients 18-65 years who attended a clinic of the CanSpA network and received treatment with secukinumab. Patients were indexed on the date they first initiated secukinumab. Retention was assessed at 12-months post-index. Clinical effectiveness was measured as proportion in remission and change in disease activity from baseline to 12-months using several clinical indices.213 patients were included. Overall retention was estimated at 73.6% at 12-months (81.8% for bt/sDMARD-naive patients). 17/110 (15.5%) patients were in DAPSA28-based remission, and 10/70 (14.3%) were in PASDAS-based remission at 12-months. PASI improved by 65.8%; TJC68 and SJC66 improved by 65.5% and 73.7%, respectively.This is the first nationwide study to describe real-world use of secukinumab in Canada for PsA, and supports its effectiveness in a Canadian real-world setting. The CanSpA network represents a unique opportunity to build and improve the real-world evidence base for SpA treatment in Canada.